TEAS RF New Application

BASILEA

Basilea Pharmaceutica AG

Trademark/Service Mark Application, Principal Register

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1478 (Rev 09/2006)
OMB No. 0651-0009 (Exp 02/28/2021)

Trademark/Service Mark Application, Principal Register

Serial Number: 88633518
Filing Date: 09/27/2019

The table below presents the data as entered.

Input Field
Entered
SERIAL NUMBER 88633518
MARK INFORMATION
*MARK \\TICRS\EXPORT17\IMAGEOUT 17\886\335\88633518\xml1\ RFA0002.JPG
SPECIAL FORM YES
USPTO-GENERATED IMAGE NO
LITERAL ELEMENT BASILEA
COLOR MARK NO
*DESCRIPTION OF THE MARK
(and Color Location, if applicable)
The mark consists of the word "BASILEA" surrounded by an oval.
PIXEL COUNT ACCEPTABLE YES
PIXEL COUNT 711 x 250
REGISTER Principal
APPLICANT INFORMATION
*OWNER OF MARK Basilea Pharmaceutica AG
*STREET Grenzacherstrasse 487
*CITY Basel
*COUNTRY Switzerland
*ZIP/POSTAL CODE
(Required for U.S. and certain international addresses)
4058
LEGAL ENTITY INFORMATION
TYPE corporation
STATE/COUNTRY OF INCORPORATION Switzerland
GOODS AND/OR SERVICES AND BASIS INFORMATION
INTERNATIONAL CLASS 001 
*IDENTIFICATION Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions, the treatment of infections and diseases and in the research and development of pharmaceuticals in the treatment of dermatological conditions, the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use
FILING BASIS SECTION 1(b)
INTERNATIONAL CLASS 005 
*IDENTIFICATION Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of allergies; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents; all of the aforesaid for prescription only
FILING BASIS SECTION 1(b)
INTERNATIONAL CLASS 042 
*IDENTIFICATION Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations
FILING BASIS SECTION 1(b)
ATTORNEY INFORMATION
NAME Evan A. Raynes
ATTORNEY BAR MEMBERSHIP NUMBER XXX
YEAR OF ADMISSION XXXX
U.S. STATE/ COMMONWEALTH/ TERRITORY XX
FIRM NAME Symbus Law Group, LLC
STREET 1775 I Street, NW, Suite 1150
CITY Washington
STATE District of Columbia
COUNTRY United States
ZIP/POSTAL CODE 20006
PHONE 202-258-0652
OTHER APPOINTED ATTORNEY Janice Bader
CORRESPONDENCE INFORMATION
NAME Evan A. Raynes
FIRM NAME Symbus Law Group, LLC
STREET 1775 I Street, NW, Suite 1150
CITY Washington
STATE District of Columbia
COUNTRY United States
ZIP/POSTAL CODE 20006
PHONE 202-258-0652
*EMAIL ADDRESS eraynes@symbus.com; legalasst@symbus.com
*AUTHORIZED TO COMMUNICATE VIA EMAIL Yes
FEE INFORMATION
APPLICATION FILING OPTION TEAS RF
NUMBER OF CLASSES 3
APPLICATION FOR REGISTRATION PER CLASS 275
*TOTAL FEE DUE 825
*TOTAL FEE PAID 825
SIGNATURE INFORMATION
SIGNATURE /Evan A. Raynes/
SIGNATORY'S NAME Evan A. Raynes
SIGNATORY'S POSITION Attorney of record, DC bar member
SIGNATORY'S PHONE NUMBER 202-258-0652
DATE SIGNED 09/27/2019



Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1478 (Rev 09/2006)
OMB No. 0651-0009 (Exp 02/28/2021)


Trademark/Service Mark Application, Principal Register

Serial Number: 88633518
Filing Date: 09/27/2019

To the Commissioner for Trademarks:

MARK: BASILEA (stylized and/or with design, see mark)
The literal element of the mark consists of BASILEA. The applicant is not claiming color as a feature of the mark. The mark consists of the word "BASILEA" surrounded by an oval.
The applicant, Basilea Pharmaceutica AG, a corporation of Switzerland, having an address of
      Grenzacherstrasse 487
      Basel 4058
      Switzerland

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

International Class 001:  Chemical substances for use in the manufacture of pharmaceutical preparations for the treatment of dermatological conditions, the treatment of infections and diseases and in the research and development of pharmaceuticals in the treatment of dermatological conditions, the treatment of infections and diseases; diagnostic preparations for scientific clinical use; diagnostic reagents for clinical or medical laboratory use
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 005:  Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of dermatological conditions, namely, eczema, inflammation, infection, warts, psoriasis, aging of the skin, ultra violet radiation and cancer; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of infections caused by bacteria, fungi, viruses, and rheumatoid arthritis; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of oncology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gastroenterology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of neurology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of gynecology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of urology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of cardiology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of endocrinology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of nephrology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of hematology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of allergies; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of immunology; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of psychiatry; Pharmaceutical and veterinary products and preparations, namely, for the treatment and prevention of diseases, disorders and conditions in the area of anesthesiology; Pharmaceutical and veterinary products and preparations for the treatment and prevention of diseases, disorders and conditions in the area of rheumatology; diagnostic preparations for medical clinical purposes; clinical medical reagents; all of the aforesaid for prescription only
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

International Class 042:  Research and development services for third parties in the field of chemical substances, pharmaceutical and veterinary products and preparations
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.




The applicant hereby appoints Evan A. Raynes. Other appointed attorneys are Janice Bader. Evan A. Raynes of Symbus Law Group, LLC, is a member of the XX bar, admitted to the bar in XXXX, bar membership no. XXX, and the attorney(s) is located at
      1775 I Street, NW, Suite 1150
      Washington, District of Columbia 20006
      United States
      202-258-0652(phone)

Evan A. Raynes submitted the following statement: The attorney of record is an active member in good standing of the bar of the highest court of a U.S. state, the District of Columbia, or any U.S. Commonwealth or territory.

The applicant's current Correspondence Information:
      Evan A. Raynes
      Symbus Law Group, LLC
      1775 I Street, NW, Suite 1150
      Washington, District of Columbia 20006
      202-258-0652(phone)
      eraynes@symbus.com; legalasst@symbus.com (authorized).

Email Authorization: I authorize the USPTO to send email correspondence concerning the application to the applicant, the applicant's attorney, or the applicant's domestic representative at the email address provided in this application. I understand that a valid email address must be maintained and that the applicant or the applicant's attorney must file the relevant subsequent application-related submissions via the Trademark Electronic Application System (TEAS). Failure to do so will result in the loss of TEAS Reduced Fee status and a requirement to submit an additional processing fee of $125 per international class of goods/services.

A fee payment in the amount of $825 has been submitted with the application, representing payment for 3 class(es).

Declaration

Declaration Signature

Signature: /Evan A. Raynes/   Date: 09/27/2019
Signatory's Name: Evan A. Raynes
Signatory's Position: Attorney of record, DC bar member
Payment Sale Number: 88633518
Payment Accounting Date: 09/27/2019

Serial Number: 88633518
Internet Transmission Date: Fri Sep 27 11:22:36 EDT 2019
TEAS Stamp: USPTO/BAS-XX.XX.XXX.XXX-2019092711223685
9274-88633518-6107a8f6fbd8e86628c2533235
97f5f36c876648897f54981a25982495790d9ca-
CC-22369755-20190927111848708180

TEAS RF New Application [image/jpeg]


uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed